Latest Funding And Investment News

Centrepoint Alliance reported a 16% rise in normalised EBITDA to $12.3 million for FY26, exceeding its guidance and lifting its EBITDA margin to 29%. The company’s adviser network grew modestly, while funds under management jumped 48%.

Celsius Resources disputes foreclosure notices from Equinaire over its 40% interest in Makilala Mining, rejecting claims of default and vowing legal defence.

Global X Management (AUS) Limited is trimming the management fee for its Australia 300 ETF (ASX: A300) by 25%, effective 1 July 2026, reflecting a subtle but meaningful cost saving for investors.

Salt Listed Funds released its 2026 annual report highlighting governance changes, investment policy updates including Treasury Units and Carbon-Related Businesses, and a notable decline in the Carbon Fund’s unit price over the year.

Smartshares Limited’s annual report for the year ending 31 March 2026 details mixed fund unit movements, notable management changes, and key investment manager transitions within its suite of Exchange Traded Funds.

Booster Innovation Fund reported a $1.593 million profit for the year ended March 2026, supported by increased net assets. However, valuation risks persist due to early-stage investments and recent capital raises at lower prices.

Booster Investment Scheme 2's Private Land and Property Fund swung back to profit with NZD 1.3 million after tax for the year ended March 2026, despite net asset value slipping due to unit redemptions. The Fund’s investment portfolio remains concentrated in unlisted New Zealand agricultural and property assets, while its Manager faces unrelated FMA proceedings.

CD Private Equity Fund I (ASX:CD1) posted a net loss of $6.96 million for the year ended 31 March 2026, driven by a $5.14 million fair value decline in its US private equity holdings and significant foreign exchange pressures. Despite near-term setbacks, the Fund has delivered an 8.3% post-tax annual return since inception.

Strata Investment Holdings has dismissed a cash acquisition proposal from Freedom BidCo, citing undervaluation, even as it raises A$8 million to fund strategic investments and litigation.

Vita Life Sciences projects a slight increase in H1 2026 sales and stable pre-tax profits, supported by strong markets in Australia and Malaysia/Singapore but offset by regulatory headwinds in China.

VanEck Investments Limited has issued a comprehensive Replacement Product Disclosure Statement for eight of its Australian ETFs, detailing investment strategies, fees, risks, and operational protocols under ASX AQUA Rules.

Flight Centre Travel Group showcased robust growth and strategic innovation at its 2026 Investor Day, navigating geopolitical challenges with AI-driven efficiency and portfolio reshaping.